Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 67.04% is in line with its 5-year average of 63.25%, around the middle of its 5-year range (50.03%–77.48%).
4.33% above its 12-month average of 64.26%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 70.93%.
GROSS MARGIN
67.04%
GROSS MARGIN AVG TTM
64.26%
GROSS MARGIN AVG 3Y
63.64%
GROSS MARGIN AVG 5Y
63.25%
GROSS MARGIN AVG 10Y
64.45%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+4.33%
CURRENT VS 3Y AVG
+5.34%
CURRENT VS 5Y AVG
+5.99%
CURRENT VS 10Y AVG
+4.01%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.91%
median of 450 covered companies
CURRENT VS SECTOR MEDIAN
+56.23%
vs the sector median at left
Aquestive Therapeutics, Inc.
Market Cap
$573.38M
Gross Margin
67.04%
TTM Avg
64.26%
3Y Avg
63.64%
5Y Avg
63.25%
Market Cap
$579.88M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$561.67M
Gross Margin
98.63%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$551.09M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$596.36M
Gross Margin
73.28%
TTM Avg
79.19%
3Y Avg
65.08%
5Y Avg
51.90%
Market Cap
$547.86M
Gross Margin
87.05%
TTM Avg
84.77%
3Y Avg
78.39%
5Y Avg
75.97%
Market Cap
$519.25M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
31.77%
Market Cap
$517.79M
Gross Margin
100.00%
TTM Avg
50.00%
3Y Avg
75.00%
5Y Avg
83.33%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | $573.38M | 67.04% | 64.26% | 63.64% | 63.25% |
| CorMedix Inc. (CRMD)vs › | $569.56M | 82.78% | 90.56% | 68.85% | 51.96% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $579.88M | 0.00% | 0.00% | 0.00% | 0.00% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $561.67M | 98.63% | 100.00% | 100.00% | 100.00% |
| Immix Biopharma, Inc. (IMMX)vs › | $551.09M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $596.36M | 73.28% | 79.19% | 65.08% | 51.90% |
| Delcath Systems, Inc. (DCTH)vs › | $547.86M | 87.05% | 84.77% | 78.39% | 75.97% |
| Altimmune, Inc. (ALT)vs › | $519.25M | 100.00% | 100.00% | 100.00% | 31.77% |
| Crescent Biopharma, Inc. (CBIO)vs › | $517.79M | 100.00% | 50.00% | 75.00% | 83.33% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $517.73M | 0.00% | 50.00% | -2215.86% | -1460.58% |
Gross Margin
67.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 70.93% |
| 2026-03-31 | 75.99% |
| 2025-12-31 | 55.16% |
| 2025-09-30 | 64.82% |
| 2025-06-30 | 54.40% |
| 2025-03-31 | 58.12% |
| 2024-12-31 | 61.91% |
| 2024-09-30 | 67.24% |
| 2024-06-30 | 77.48% |
| 2024-03-31 | 63.59% |
| 2023-12-31 | 64.57% |
| 2023-09-30 | 63.10% |
| 2023-06-30 | 50.03% |
| 2023-03-31 | 57.45% |
| 2022-12-31 | 50.34% |
| 2022-09-30 | 59.65% |
| 2022-06-30 | 60.48% |
| 2022-03-31 | 65.66% |
| 2021-12-31 | 69.62% |
| 2021-09-30 | 66.88% |
| 2021-06-30 | 70.90% |
| 2021-03-31 | 75.21% |
| 2020-12-31 | 61.00% |
| 2020-09-30 | 63.95% |
| 2020-06-30 | 83.67% |
| 2020-03-31 | 58.25% |
| 2019-12-31 | 58.63% |
| 2019-09-30 | 62.61% |
| 2019-06-30 | 51.30% |
| 2019-03-31 | 72.27% |
| 2018-12-31 | 71.55% |
| 2018-09-30 | 57.85% |
| 2018-06-30 | 64.29% |
| 2018-03-31 | 75.93% |
| 2017-12-31 | 53.96% |
| 2017-09-30 | 82.02% |
| 2017-06-30 | 53.86% |
| 2017-03-31 | 74.54% |
